The Long YM Bio Nightmare Has Ended -- Happily.

by Web Master, Benzinga Editor
December 12, 2012 9:04 AM | 5 seconds read |
Gilead acquires YM Bio for $510 million in cash to grow its cancer drug pipeline.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!